Considering this role of extracellular ADO in regulating inflammation and immunogenicity, evidence emphasizes the Non-Conical Pathway (CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39) could constitute a novel strategy for tumor evasion, implying that these enzymes may represent ideal targets for antibody-mediated therapy16–20. This evidence concerns the gene CD38 and neoplasm.